Gilead to Pay Merck $2.54B Over Hep C Royalties

Dec 15, 2016

Merck & Co have been awarded $2.54 billion in royalties by a federal jury in Delaware for a patent lawsuit against Gilead Sciences. The case was over Sovaldi and Harvoni, Gilead's blockbuster hepatitis C drugs

The patent upheld by the jury was originally issued to Idenix Pharmaceuticals, which was acquired by Merck in 2014.

In February, a compound in Gilead’s Sovaldi and Harvoni was found by a judge to have infringed Merck’s patents, and  Merck sued Gilead for more than $3 billion in a patent dispute. On March 24, an order from a federal jury had Gilead set to pay $200M in damages to Merck, but the decision was overturned in June.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments